Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) will release its second-quarter financial results on August 17, 2021, before U.S. markets open. A conference call is scheduled for 8:00 a.m. ET to discuss these results alongside recent business developments. Gracell focuses on developing innovative cell therapies for cancer, addressing major challenges in CAR-T treatments. The company utilizes its FasTCAR and TruUCAR technology platforms to enhance production quality and reduce costs.

Positive

• Upcoming financial results may indicate progress in Gracell's business strategy.
• Gracell's innovative approach may lead to cost-effective and efficient cell therapies.

Negative

• None.

SUZHOU, China and PALO ALTO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will release financial results for the second quarter ended June 30, 2021, prior to the open of the U.S. financial markets on Tuesday, August 17. Gracell’s management team will host a corresponding conference call beginning at 8:00 a.m. Eastern Time to discuss the financial results and recent business developments. A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

Conference call and webcast details:

Tuesday, August 17, 2021 @ 8:00am ET

Investor domestic dial-in: 877-407-0784

Investor international dial-in: +1 201-689-8560

Conference ID: 13722146

Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com

Follow @GracellBio on LinkedIn

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

FAQ

When will Gracell Biotechnologies release its financial results for Q2 2021?

Gracell Biotechnologies will release its financial results for the second quarter on August 17, 2021.

What time is the Gracell conference call scheduled for?

The conference call is scheduled for 8:00 a.m. ET on August 17, 2021.

What is Gracell Biotechnologies' stock symbol?

Gracell Biotechnologies' stock symbol is GRCL.

What technology platforms does Gracell use for its therapies?

Gracell uses the FasTCAR and TruUCAR technology platforms in its cell therapy development.

What challenges does Gracell aim to overcome in CAR-T therapies?

Gracell aims to address lengthy manufacturing times, high costs, and the lack of effective therapies for solid tumors.